High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification

Siel Olbrecht(The European Academy of Gynaecological Surgery), Ignace Vergote(KU Leuven)

Genome Medicine

July 8, 2021

10.1186/s13073-021-00922-x

Cited by 194

Related Papers

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

|New England Journal of Medicine|2016|2.5k

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

|Annals of Oncology|2019|1.2k

Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

|Journal of Clinical Oncology|2000|840

Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group

|BMJ|2010|473

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

|The Lancet Oncology|2021|412